摘要
重组人溶菌酶是经生物技术改构后产生的一类对G+和G-菌都有抗菌效应的一类新药。临床前数据表明它对1 040株致病菌具有抗菌活性,最低抑菌浓度(MIC)范围为0．125～>4000μg·mL-1;此外,它还有抑制冠状病毒、抗炎和镇痛作用。现综述其药效学、毒理学和药动学的研究情况。新型重组人溶菌酶在体内外均安全和有效,有望开发成为新型抗感染药物。
A new human lysozyme made by recombinant techniques shows effectiveness in killing selectively Gram-negative bacteria as well as Gram-positive bacteria. Preclinical data indicated that the recombinant human lysozyme （rhLZ） significantly inhibited 1 040 strains of bacteria growth with a MIC of 0. 125 - 〉 4 000μg·mL^-1. The rhLZ shows significant susceptibilities against coronaviruses and inflammatory infection together with analgesic activity. This review discussed the toxicology, pharmacodynamics and pharmacokinetics of rhLZ. The rhLZ has the potential to be an effective and safe antimicrobials against the causative agent
出处
《中国新药杂志》
CAS
CSCD
北大核心
2006年第17期1436-1439,共4页
Chinese Journal of New Drugs
关键词
重组人溶菌酶
药效学
毒理
药动学
recombinant human lysozyme
pharmacodynamics
toxicity
pharmocokinetics
